Tradestie Institutional Equity Comparison Engine
AVDL vs HROW โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Overall Edge
AVDL Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus HROW at 62.9x Forward P/E and -2.0% operating margin (+38.6% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against HROW sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
AVDL
AVDL 28.8x vs HROW 62.9x Fwd P/E
Growth & Margin Winner
AVDL
Op Margin 2.5% vs -2.0% ยท YoY +54.9% vs +38.6%
Momentum & Technical Winner
AVDL
1Y +138.1% vs -23.2% ยท 52W Pos 89% vs 16%
Options & Structure Winner
AVDL
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (8th %ile IV)
AVDL
NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap
$2.1B
1M Return
+0.65%
1Y Return
+138.06%
Forward P/E
28.8x
Unified AI Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
HROW
NASDAQ
Harrow, Inc. Common Stock
Pharmaceutical Preparations
$30.41
-5.35% 1D
Market Cap
$1.2B
1M Return
+8.03%
1Y Return
-23.21%
Forward P/E
62.9x
Unified AI Score
32.2 / 100
SELL
Tech 20.0
Fund 43.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AVDL +138.06%
HROW -23.21%
Spread: +29.2 pp (HROW Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AVDL TTM Op. Margin: 2.5%
HROW TTM Op. Margin: -2.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs HROW. Trailing 12-month operating profitability (AVDL 2.5% vs HROW -2.0%) and valuation multiples (AVDL 28.8x vs HROW 62.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | HROW | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.2B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 16.8x | 62.9x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 28.8x | 62.9x | Lower Multiple | AVDL |
| Revenue Growth (YoY) Growth | +54.9% | +38.6% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | -2.0% | Higher Margin | AVDL |
| Net Profit Margin Profitability | -0.1% | -9.4% | Higher Margin | AVDL |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -75.5% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 16% ($26โ$55) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 1.08ฮฒ ยท 72% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 32.2 / 100 (SELL) | Higher Composite | AVDL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AVDL vs HROW Buy Guide
AVDL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
HROW
BREAKDOWN
89d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AVDL nor HROW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.